Contract Pharma Staff11.10.20
MercachemSyncom, a leading mid-sized European drug-discovery contract research organization, has acquired Admescope Ltd. based in Oulu, Finland and Södertälje, Sweden.
The acquisition will give MercachemSyncom significantly expanded capabilities for tailor-made in vitro and in vivo ADME-Tox studies for pre-clinical and early clinical R&D projects and seamless integration with the existing medicinal, synthetic and development chemistry capabilities of MercachemSyncom. Admescope brings expertise in drug metabolism, drug interactions, pharmacokinetics and quantitative bioanalysis. Financial terms were not disclosed.
Admescope has seen significant growth in subsequent years and currently employs 40 highly qualified and experienced scientists. The scientific and management teams have consolidated experience in tailored ADME-Tox studies for pharma and biotech clients all over the world. Studies are carried out at research laboratories in both Oulu and Södertälje, Sweden with emphasis on a deep understanding of customers' needs, in-house processes and how to design the most effective studies to satisfy them.
'A Perfect Match'
Eelco Ebbers, CEO of MercachemSyncom, says he is happy to welcome Admescope to MercachemSyncom.
“MercachemSyncom is at the forefront of a continuing consolidation of high-quality contract research and manufacturing organizations into medium-sized, but still agile, companies able to offer an extended palette of R&D services to long-standing and new clients,” he remarked.
Ebbers continued, “I am convinced that the addition of Admescope, a world-class company offering high quality, innovative and client-centric ADME-Tox services to our organization is a perfect match, both in terms of complementarity and working philosophy… This approach fits perfectly with MercachemSyncom's approach to discovery and development.”
Ari Tolonen, CEO of Admescope, added, "We are thrilled to continue our successful growth as a part of MercachemSyncom. We feel that the cultural fit between our companies is excellent, and with the support of MercachemSyncom we will be able to continue meeting and exceeding our customers’ expectations for contract research services.”
“MercachemSyncom’s global presence greatly increases our exposure to new companies that we can help with our ADME-Tox services. While Admescope’s focus will remain in providing our existing and new customers with the top-quality services and customer experience that they are used to, together with MercachemSyncom we can offer a wider spectrum of services to cover the needs of our customers, as well as further expand our service offering,” Tolonen concluded.
The acquisition will give MercachemSyncom significantly expanded capabilities for tailor-made in vitro and in vivo ADME-Tox studies for pre-clinical and early clinical R&D projects and seamless integration with the existing medicinal, synthetic and development chemistry capabilities of MercachemSyncom. Admescope brings expertise in drug metabolism, drug interactions, pharmacokinetics and quantitative bioanalysis. Financial terms were not disclosed.
Admescope has seen significant growth in subsequent years and currently employs 40 highly qualified and experienced scientists. The scientific and management teams have consolidated experience in tailored ADME-Tox studies for pharma and biotech clients all over the world. Studies are carried out at research laboratories in both Oulu and Södertälje, Sweden with emphasis on a deep understanding of customers' needs, in-house processes and how to design the most effective studies to satisfy them.
'A Perfect Match'
Eelco Ebbers, CEO of MercachemSyncom, says he is happy to welcome Admescope to MercachemSyncom.
“MercachemSyncom is at the forefront of a continuing consolidation of high-quality contract research and manufacturing organizations into medium-sized, but still agile, companies able to offer an extended palette of R&D services to long-standing and new clients,” he remarked.
Ebbers continued, “I am convinced that the addition of Admescope, a world-class company offering high quality, innovative and client-centric ADME-Tox services to our organization is a perfect match, both in terms of complementarity and working philosophy… This approach fits perfectly with MercachemSyncom's approach to discovery and development.”
Ari Tolonen, CEO of Admescope, added, "We are thrilled to continue our successful growth as a part of MercachemSyncom. We feel that the cultural fit between our companies is excellent, and with the support of MercachemSyncom we will be able to continue meeting and exceeding our customers’ expectations for contract research services.”
“MercachemSyncom’s global presence greatly increases our exposure to new companies that we can help with our ADME-Tox services. While Admescope’s focus will remain in providing our existing and new customers with the top-quality services and customer experience that they are used to, together with MercachemSyncom we can offer a wider spectrum of services to cover the needs of our customers, as well as further expand our service offering,” Tolonen concluded.
